Biotech Giants Performance Comparison

As of now, Gilead, Amgen, Vertex, Regeneron, and Biogen have all released their performance reports. Details are as follows:

1. Vertex

Vertex, one of the most valuable biotech companies in the U.S., released its 2024 earnings report on February 10. The company reported annual revenue of $11.02 billion, an 11.67% year-over-year increase, but a net loss of $536 million, primarily due to the acquisition of Alpine.

Since 2023, Vertex has had a series of successes:

• FDA approval for expanded indications of Trikafta and Kalydeco.
• FDA approval for the world’s first gene-editing therapy, Casgevy (exagamglogene autotemcel).
• Significant clinical progress in its stem cell therapy for Type 1 diabetes.
• Successful completion of clinical trials for the next-generation CF triple therapy Vanza (vanzacaftor + tezacaftor + deutivacaftor) and the novel non-opioid painkiller suzetrigine.
• Positive clinical trial data for its IgA nephropathy drug, povetacicept.

Driven by these breakthroughs, Vertex’s stock price repeatedly hit record highs, with its market capitalization once approaching $140 billion, making it the second-largest biotech giant globally (behind Amgen).

Drug Sales: $11.02 billion

R&D Investment: $3.63 billion

Market Capitalization: $121 billion

2. Amgen

Amgen, the world’s largest biotech company, released its 2024 earnings report on February 4. The company reported total revenue of $33.4 billion, including $32.026 billion from drug sales, ranking 13th among global pharmaceutical giants. Due to its acquisition of Horizon last year, Amgen’s sales surged, but net profit declined to $4.09 billion.

Facing patent cliffs on several key products, Amgen has aggressively pursued acquisitions to maintain growth. From 2020-2024, CEO Bradway led acquisitions of Five Prime ($1.9 billion), Teneobio ($2.5 billion), and Horizon ($27.8 billion), adding bemarituzumab and teprotumumab to its portfolio and expanding into rare disease treatments. While these mergers restored revenue growth, they also resulted in a heavy debt burden, with an average debt ratio of 94% from 2022-2024.

Drug Sales: $32.026 billion

R&D Investment: $5.09 billion

Market Capitalization: $159.3 billion

3. Gilead

Gilead, the third-largest biotech company by market value, released its 2024 earnings on February 11. The company reported total revenue of $28.754 billion, with drug sales of $28.61 billion, ranking 15th among global pharmaceutical giants. Net profit stood at $480 million, marking a significant decline from the previous year.

With the HIV treatment market maturing and the hepatitis C market shrinking rapidly, Gilead has been forced to diversify its pipeline. Heavy investments in expansion have led to a high debt ratio, averaging 67% from 2017-2024, peaking at 73% in 2020. Weak sales in oncology and immunosuppressant drugs have resulted in low investment returns, slow net asset growth, and a persistently low market valuation since 2016.

Drug Sales: $28.61 billion

R&D Investment: $5.907 billion

Market Capitalization: $119.8 billion

4. Regeneron

Regeneron released its 2024 earnings report on February 4, reporting an 8% revenue increase to $14.2 billion and a 12% net profit increase to $4.413 billion. The company's primary revenue driver is EYLEA (aflibercept), with U.S. sales rising 1% to $5.968 billion (sales outside the U.S. are handled by Bayer). Libtayo, Regeneron's second-largest product, saw a 41% increase in global sales to $1.217 billion. The company also sells Praluent, Evkeeza, and Inmazeb in the U.S., with 2024 sales of $242 million, $126 million, and $76 million, respectively (Sanofi handles sales outside the U.S.).

Drug Sales: $7.629 billion

R&D Investment: $5.132 billion

Market Capitalization: $72.8 billion

5. Biogen

On February 12, Biogen released its financial report, showing total revenue of $9.675 billion in 2024, a 2% decline, and a net profit of $1.632 billion, up $500 million year-over-year. In recent years, Biogen has struggled with innovation, as multiple blockbuster multiple sclerosis drugs face patent cliffs, leading to significant declines in sales and stock value.

Drug Sales: $7.214 billion

R&D Investment: $2.042 billion

Market Capitalization: $19.1 billion

Challenges of Biotech Giants

Like pharmaceutical giants, biotech companies also face innovation fatigue as they reach a certain scale. Two key reasons for this are:

1. Biotech companies typically originate from a single pioneering technology, and each technology or target has a finite number of drug possibilities. Once a technology or target is fully exploited, biotech companies must branch into new areas, requiring cross-disciplinary research and dealing with knowledge and technical barriers. This can lead to path dependency and even complacency.
2. As companies grow larger, bureaucratic processes increase, reducing organizational flexibility.

To combat innovation fatigue, biotech firms need to engage in mergers and acquisitions or continuously acquire smaller biotech companies to diversify their R&D pipelines.